论文部分内容阅读
采用 SABC免疫组织化学方法检测了 71例肺癌患者 (肺癌组 )癌组织中 P1 6蛋白和血管内皮生长因子(VEGF)的表达情况 ,并与 2 0例肺良性病变患者 (对照组 )比较。结果肺癌组的 P1 6 蛋白阳性率为 5 3.5 2 % ,明显低于对照组 (90 % ) ,P<0 .0 1;有淋巴结转移者的 P1 6蛋白阳性率显著低于无淋巴结转移者 ;肺癌分期为 ～ 期者 P1 6蛋白阳性率显著低于 ～ 期者。肺癌组 VEGF阳性率为 71.83% ,明显高于对照组 (2 0 % ) ,P<0 .0 1;吸烟量少者VEGF阳性率显著高于吸烟量多者 ,肿瘤低分化者显著高于高分化者 ,有淋巴结转移者显著高于无淋巴结转移者 ,肺癌为 ～ 期者显著高于 ～ 期者。证实肺癌中 P1 6 蛋白与 VEGF呈负相关 ;P1 6 蛋白及 VEGF表达均为判断肺癌预后的指标
The expression of P1 6 protein and vascular endothelial growth factor (VEGF) in 71 lung cancer patients (lung cancer group) were detected by SABC immunohistochemistry and compared with 20 benign lung disease patients (control group). Results The positive rate of P1 6 protein in lung cancer was 53.5%, significantly lower than that in control group (90%) (P <0.01). The positive rate of P1 6 protein in patients with lymph node metastasis was significantly lower than those without lymph node metastasis The positive rate of P1 6 protein in stage of lung cancer was significantly lower than that in stage Ⅲ. The positive rate of VEGF in lung cancer group was 71.83%, which was significantly higher than that in control group (20%), P <0.01; the positive rate of VEGF was lower in smokers than in smokers Differentiation, those with lymph node metastasis were significantly higher than those without lymph node metastasis, lung cancer ~ period was significantly higher than ~ period. Confirmed that lung cancer P1 6 protein and VEGF was negatively correlated; P1 6 protein and VEGF expression are indicators to determine the prognosis of lung cancer